Compare Merck & Co., Inc. (MRK) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while First Trust NASDAQ 100 Technology Index Fund trades at $310.91. The key difference: Merck & Co., Inc. pays a 2.29% dividend while First Trust NASDAQ 100 Technology Index Fund pays none. Which is the better fit depends on your goals.
| MRK | QTEC | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $156.43 | $335.74 |
52-Week Low | $77.60 | $207.03 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
QTEC trades at $311.57, down 0.22% with neutral technical signals. The ETF shows bearish moving averages but neutral oscillators, with key support at $310 and resistance at $313. Recent coverage highlights its equal-weighted tech exposure and liquidity advantages over peers like RSPT, with software appearing undervalued relative to historical averages according to Seeking Alpha analysis.
The technology sector ETF offers diversified exposure but faces typical sector volatility risks. Current technical positioning suggests limited near-term momentum, while fundamental analysis indicates selective value opportunities within the portfolio components. Market sentiment remains balanced between growth potential and valuation concerns in the tech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
